|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Other
Indications for Tysabri
Elan and Biogen Idec continue to explore additional indications
for Tysabri, including oncology and ulcerative colitis.
An Investigational New Drug (IND) application was filed for
Tysabri for multiple myeloma in 2007 and a proof of
concept study is planned for the first half of 2008.
Table of Contents
|
| |||||||